Table 8. Multivariate analysis of various clinical factors on survivals of locally advanced nasopharyngeal carcinoma (n = 553).

Survival	Factor	p value	HR(95%CI)
LRFS	Gender (female vs. male)	0.041	0.451(0.210–0.968)
	Radiation Boost (yes vs. no)	0.004	2.400(1.317–4.376)
RRFS	N stage (N3/N2/N1/N0)	0.034	1.613(1.037–2.508)
	Radiation Boost (yes vs. no)	0.001	3.432(1.653–7.125)
DMFS	Gender (female vs. male)	0.004	0.374(0.191–0.731)
	T stage (T4/T3/T2/T1)	0.002	1.526(1.174–1.984)
	N stage (N3/N2/N1/N0)	0.001	1.616(1.209–2.159)
	Total dose of cisplatin (≥300 vs. < 300 mg/m2)	0.004	0.501(0.313–0.800)
	Radiation Boost (yes vs. no)	0.009	2.085(1.200–3.622)
DFS	Gender (female vs. male)	0.004	0.515(0.327–0.811)
	T stage (T4/T3/T2/T1)	0.016	1.650(1.096–2.485)
	N stage (N3/N2/N1/N0)	0.028	1.567(1.049–2.342)
	Total dose of cisplatin (≥300 vs. < 300 mg/m2)	0.036	0.688(0.486–0.976)
	Radiation boost (yes vs. no)	0.001	1.932(1.290–2.892)
OS	Age (>48 vs. ≤ 48)	0.031	1.662(1.047–2.639)
	T stage (T4/T3/T2/T1)	0.024	1.361(1.041–1.779)
	N stage (N3/N2/N1/N0)	0.001	1.699(1.254–2.300)
	Total dose of cisplatin (≥300 vs. < 300 mg/m2)	0.012	0.554(0.350–0.879)